NASDAQ:PULM Pulmatrix (PULM) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free PULM Stock Alerts $2.03 -0.05 (-2.40%) (As of 02:31 PM ET) Add Compare Share Share Today's Range$2.00▼$2.0750-Day Range$1.62▼$2.1652-Week Range$1.55▼$3.14Volume5,908 shsAverage Volume17,317 shsMarket Capitalization$7.41 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Pulmatrix alerts: Email Address Pulmatrix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside392.6% Upside$10.00 Price TargetShort InterestHealthy0.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.46 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPulmatrix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePulmatrix has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.32% of the float of Pulmatrix has been sold short.Short Interest Ratio / Days to CoverPulmatrix has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmatrix has recently increased by 325.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmatrix does not currently pay a dividend.Dividend GrowthPulmatrix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PULM. Previous Next 1.4 News and Social Media Coverage News SentimentPulmatrix has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pulmatrix this week, compared to 0 articles on an average week.Search Interest1 people have searched for PULM on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmatrix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.61% of the stock of Pulmatrix is held by insiders.Percentage Held by InstitutionsOnly 11.84% of the stock of Pulmatrix is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmatrix is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmatrix is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmatrix has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Pulmatrix Stock (NASDAQ:PULM)Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Read More PULM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PULM Stock News HeadlinesApril 24, 2024 | americanbankingnews.comPulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.comMarch 28, 2024 | investorplace.comPULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023April 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 28, 2024 | finanznachrichten.dePulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | prnewswire.comPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdateFebruary 15, 2024 | morningstar.comCipla Ltd CIPLAJanuary 10, 2024 | bizjournals.comFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersJanuary 9, 2024 | bizjournals.comPulmatrix shuts down study, explores saleApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 8, 2024 | nasdaq.comPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The StudyJanuary 8, 2024 | marketwatch.comPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic AlternativesJanuary 8, 2024 | finance.yahoo.comPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic AlternativesJanuary 8, 2024 | msn.comStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata SteelJanuary 8, 2024 | msn.comStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In FocusNovember 12, 2023 | morningstar.comPulmatrix Inc PULMNovember 9, 2023 | baystreet.caPulmatrix Down on Q3 ResultsNovember 9, 2023 | msn.comPulmatrix GAAP EPS of -$1.03, revenue of $1.75MNovember 9, 2023 | finance.yahoo.comPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 23, 2023 | finance.yahoo.comAspergillosis Treatment Research Report 2023September 19, 2023 | markets.businessinsider.comPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100September 19, 2023 | finance.yahoo.comPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigraineSeptember 11, 2023 | msn.comPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock NowAugust 23, 2023 | finance.yahoo.comPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazoleAugust 10, 2023 | finanznachrichten.dePulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 10, 2023 | msn.comPulmatrix GAAP EPS of -$1.04, revenue of $1.84MAugust 10, 2023 | finance.yahoo.comPulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 11, 2023 | finance.yahoo.comPulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute MigraineSee More Headlines Receive PULM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PULM CUSIPN/A CIK1574235 Webwww.pulmatrix.com Phone(781) 357-2333Fax707-525-9906Employees22Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+380.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,120,000.00 Net Margins-193.49% Pretax Margin-193.49% Return on Equity-63.94% Return on Assets-40.88% Debt Debt-to-Equity RatioN/A Current Ratio5.33 Quick Ratio5.33 Sales & Book Value Annual Sales$7.30 million Price / Sales1.04 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book0.42Miscellaneous Outstanding Shares3,650,000Free Float3,520,000Market Cap$7.59 million OptionableNot Optionable Beta0.92 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Teofilo David Raad MBA (Age 54)President, CEO & Director Comp: $577.72kMr. Peter Ludlum CMA (Age 69)MBA, Interim CFO and Principal Accounting & Financial Officer Comp: $510.22kDr. Alexander M. Klibanov Ph.D. (Age 74)Founder Key CompetitorsPHAXIAM TherapeuticsNASDAQ:PHXMEiger BioPharmaceuticalsNASDAQ:EIGRTevogen BioNASDAQ:TVGNPasithea TherapeuticsNASDAQ:KTTAChemomab TherapeuticsNASDAQ:CMMBView All Competitors PULM Stock Analysis - Frequently Asked Questions Should I buy or sell Pulmatrix stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PULM shares. View PULM analyst ratings or view top-rated stocks. What is Pulmatrix's stock price target for 2024? 1 brokers have issued twelve-month target prices for Pulmatrix's stock. Their PULM share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 392.6% from the stock's current price. View analysts price targets for PULM or view top-rated stocks among Wall Street analysts. How have PULM shares performed in 2024? Pulmatrix's stock was trading at $1.86 at the beginning of the year. Since then, PULM shares have increased by 9.1% and is now trading at $2.03. View the best growth stocks for 2024 here. Are investors shorting Pulmatrix? Pulmatrix saw a increase in short interest in April. As of April 15th, there was short interest totaling 11,500 shares, an increase of 325.9% from the March 31st total of 2,700 shares. Based on an average daily trading volume, of 15,400 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.3% of the company's stock are sold short. View Pulmatrix's Short Interest. When is Pulmatrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our PULM earnings forecast. How were Pulmatrix's earnings last quarter? Pulmatrix, Inc. (NASDAQ:PULM) posted its quarterly earnings results on Thursday, March, 28th. The biotechnology company reported ($0.57) EPS for the quarter. The biotechnology company had revenue of $2.20 million for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative trailing twelve-month return on equity of 63.94%. When did Pulmatrix's stock split? Pulmatrix shares reverse split on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Pulmatrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK). How do I buy shares of Pulmatrix? Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PULM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
